Treace Medical Concepts Inc

$ 1.94

3.74%

17 Apr - close price

  • Market Cap 121,147,000 USD
  • Current Price $ 1.94
  • High / Low $ 1.98 / 1.86
  • Stock P/E N/A
  • Book Value 1.37
  • EPS -0.93
  • Next Earning Report 2026-05-14
  • Dividend Per Share N/A
  • Dividend Yield 0 %
  • Next Dividend Date -
  • ROA -0.17 %
  • ROE -0.59 %
  • 52 Week High 7.78
  • 52 Week Low 1.17

About

Treace Medical Concepts, Inc., an orthopedic medical device company, is dedicated to the design, manufacture, and marketing of biological devices and / or solutions for foot and ankle surgeons in the United States. The company is headquartered in Ponte Vedra Beach, Florida.

Analyst Target Price

$4.25

Quarterly Earnings

Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Reported Date 2026-02-262025-11-062025-08-072025-05-052025-02-252024-11-052024-08-062024-05-072024-02-272023-11-092023-08-082023-05-08
Reported EPS -0.0783-0.26-0.28-0.2468-0.0016-0.25-0.29-0.3-0.1-0.28-0.2-0.23
Estimated EPS -0.1521-0.28-0.29-0.3022-0.0427-0.27-0.29-0.3-0.09-0.26-0.24-0.23
Surprise 0.07380.020.010.05540.04110.0200-0.01-0.020.040
Surprise Percentage 48.5207%7.1429%3.4483%18.3322%96.2529%7.4074%0%0%-11.1111%-7.6923%16.6667%0%

Next Quarterly Earnings

Mar 2026
Reported Date 2026-05-14
Fiscal Date Ending 2026-03-31
Estimated EPS -0.27
Currency USD

Next Dividend Records

Dividend per share (year): -
Dividend Yield -
Next Dividend Date -
Ex-Dividend Date -

Recent News: TMCI

Treace Medical Concepts (TMCI) price target increased by 12.28% to 4.08

2026-04-12 21:38:58

The article reports that the price target for Treace Medical Concepts (TMCI) has been increased by 12.28%, raising it to 4.08. No further details about the reasons for this change or the analyst responsible are provided in the snippet.

Treace Medical Concepts (TMCI) price target increased by 12.28% to 4.08

2026-04-11 21:09:38

This article reports that the price target for Treace Medical Concepts (TMCI) has been increased by 12.28%, reaching $4.08. This adjustment suggests a more optimistic outlook by analysts for the company's stock performance.

Treace Medical Concepts (TMCI) price target increased by 12.28% to 4.08

2026-04-11 19:39:41

The price target for Treace Medical Concepts (TMCI) has been increased by 12.28% to 4.08. This adjustment reflects an updated valuation for the company's stock.

...
Wall Street Zen Upgrades Treace Medical Concepts (NASDAQ:TMCI) to Sell

2026-04-11 05:39:10

Wall Street Zen has upgraded Treace Medical Concepts (NASDAQ:TMCI) from a "strong sell" to a "sell" rating, despite the company's persistent fundamental weaknesses including negative EPS, net margin, and ROE. Overall analyst sentiment remains bearish, with a consensus "Reduce" rating and a target price of $4.77. The article highlights recent analyst downgrades, institutional trading activity, and the company's focus on its Lapiplasty 3D Bunion Correction System.

...
Treace Medical Concepts Announces Leadership Transition and Outlook

2026-04-10 22:09:12

Treace Medical Concepts announced a leadership transition, with Chief Commercial Officer Gaetano M. Guglielmino departing and his duties redistributed. The company also reported preliminary unaudited revenue for Q1 2026 between $47.0 million and $47.2 million, and updated its 2026 revenue outlook to $202 million to $212 million. Analysts currently rate TMCI as a Hold with a $1.00 price target, and TipRanks’ AI Analyst, Spark, rates it as Neutral due to persistent losses and a bearish technical trend.

Stifel maintains Hold on Treace Medical stock, $3 target unchanged

2026-04-09 15:40:24

Stifel reiterated a Hold rating on Treace Medical Concepts Inc. (NASDAQ: TMCI) with an unchanged price target of $3.00, despite the stock being down 81% over the past year. The firm noted that first-quarter sales still represent a year-over-year decline but expressed encouragement that management is setting reasonable targets. Investors should consider that the company is quickly burning through cash, highlighting a key challenge in its turnaround process.